Updated Efficacy Outcomes of Anti-PD-1 Antibodies plus Multikinase Inhibitors for Patients with Advanced Gastric Cancer with or without Liver Metastases in Clinical Trials

PURPOSE: We previously reported preliminary activity of regorafenib plus nivolumab (REGONIVO) or lenvatinib plus pembrolizumab (LENPEM) in advanced gastric cancer (AGC). Meanwhile, several studies demonstrated liver metastases are less responsive to immunotherapy. PATIENTS AND METHODS: Combined effi...

Descripción completa

Detalles Bibliográficos
Autores principales: Yukami, Hiroki, Kawazoe, Akihito, Lin, Yi-Tzu, Koyama, Shohei, Fukuoka, Shota, Hara, Hiroki, Takahashi, Naoki, Kojima, Takashi, Asayama, Masako, Yoshii, Takako, Bando, Hideaki, Kotani, Daisuke, Nakamura, Yoshiaki, Kuboki, Yasutoshi, Mishima, Saori, Wakabayashi, Masashi, Kuwata, Takeshi, Goto, Masahiro, Higuchi, Kazuhide, Yoshino, Takayuki, Doi, Toshihiko, Nishikawa, Hiroyoshi, Shitara, Kohei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Clinical Trials: Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9662898/
https://www.ncbi.nlm.nih.gov/pubmed/35679062
http://dx.doi.org/10.1158/1078-0432.CCR-22-0630

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9662898/
https://www.ncbi.nlm.nih.gov/pubmed/35679062
http://dx.doi.org/10.1158/1078-0432.CCR-22-0630

Ejemplares similares